Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

96 CARBOPLATIN
Depigmentation
(1990): Costello SA+, Clin Oncol R Coll Radiol 2, 182
Edema
(2004): Furugen Y+, Gan To Kagaku Ryoho 31(8), 1205 (30%)
(with docetaxel)
Erythema (2%)
(2001): Robinson JB+, Gynecol Oncol 82(3), 550
(1995): Inbar M+, Anticancer Drugs 6, 775
Exanthems
(1995): Inbar M+, Anticancer Drugs 6, 775
(1992): Beyer J+, Bone Marrow Transplant 10, 491
(1989): Wagstaff AJ+, Drugs 37, 162
Facial edema
(1992): Beyer J+, Bone Marrow Transplant 10, 491
Hand–foot syndrome
(2001): Verschraegen CF+, Cancer 92(9), 2327 (with doxorubicin)
Palmar fasciitis
(2006): Ollivier Y+, Rev Med Interne 27(4), 346
Photo-recall
(2006): Pinson PJ+, Ned Tijdschr Geneeskd 150(34), 1891
(myositis) (with gemcitabine)
Pigmentation
(1992): Beyer J+, Bone Marrow Transplant 10, 491
(1991): Singal R+, Pediatr Dermatology 8, 231
Pruritus (2%)
(2001): Robinson JB+, Gynecol Oncol 82(3), 550
Rash (sic) (2%)
(2006): Winkeljohn D+, Clin J Oncol Nurs 10(5), 595
Raynaud’s phenomenon
(2003): Clowse ME+, J Rheumatol 30(6), 1341 (with gemcitabine)
Scleroderma
(2002): Karim M+, Clin Nephrol 58(5), 384
Urticaria (2%)
(2004): Lee CW+, Gynecol Oncol 95(2), 370
(1996): Broome CB+, Med Pediatr Oncol 26, 105
(1995): Sredni B+, J Clin Oncol 13, 2342
Mucosal
Mucositis
(2002): Rein DT+, Gynecol Oncol 87(1), 98 (with docetaxel)
Oral lesions
(1989): Wagstaff AJ+, Drugs 37, 162
Stomatitis (>10%)
Hair
Hair – alopecia (3%)
(2002): Lancet 360(9332), 505 (with paclitaxel)
(2002): de Jonge ME+, Bone Marrow Transplantation 30, 593
(permanent) (with cyclophosphamide and thiotepa)
(2002): Rein DT+, Gynecol Oncol 87(1), 98 (with docetaxel)
(2002): Sehouli J+, Gynecol Oncol 85(2), 321 (with paclitaxel)
(1989): Wagstaff AJ+, Drugs 37, 162
Hair – alopecia areata
(2003): Motl SE+, Pharmacotherapy 23(1), 104 (recurrent) (with
paclitaxel)
(2002): Rein DT+, Gynecol Oncol 87(1), 98
Hair – alopecia totalis
(2006): Pignata S+, BMC Cancer 6, 202 (with paclitaxel)
Nails
Nails – leukonychia
(2002): Lehoczky O+, JObstetGynaecol22(6), 694 (with
paclitaxel)
Eyes
Optic neuropathy
(2006): Schmack I+, Am J Ophthalmol 142(2), 310
Other
Anaphylactoid reactions/Anaphylaxis (10%)
Nephrotoxicity
(2007): Stohr W+, Pediatr Blood Cancer 48(2), 140 (mild)
(2006): Ozguroglu M+, Int J Gynecol Cancer 16 Suppl 1, 394
(with paclitaxel)
(2003): Miyazaki J+, Nippon Rinsho 61(6), 973
(2001): Kintzel PE, Drug Saf 24(1), 19
(2000): Gerke P+, J Cancer Res Clin Oncol 126(3), 173
(1998): Agraharkar M+, Am J Kidney Dis 32(5), E5
(1997): Beyer J+, Bone Marrow Transplant 20(10), 813
Neurotoxicity
(2006): Bamias A+, BMC Cancer 6, 228 (with paclitaxel)
(2006): Bell J+, Gynecol Oncol 102(3), 432 (with paclitaxel)
(2006): Pignata S+, BMC Cancer 6, 202 (with paclitaxel)
(2004): Furugen Y+, Gan To Kagaku Ryoho 31(8), 1205 (6%)
(with docetaxel)
Thrombosis
(2006): Yeung KK+, Vascular 14(1), 51
CARISOPRODOL
Synonyms: carisoprodate; isobamate
Trade names: Artifar; Carisoma; Myolax; Sanoma; Sodol; Soma
(MedPointe); Somadril; Soridol
Indications: Painful musculoskeletal disorders
Category: Central muscle relaxant
Half-life: 4–6 hours
Clinically important, potentially hazardous interactions
with: eucalyptus
Skin
Angioedema (1–10%)
Diaphoresis
Reactions